The upregulation of PD-L1 is related to the formation of resistance to BRAF inhibitors.92 A phase Ib trial demonstrated the use of BRAF and MEK inhibitors (cobimetinib and vemurafenib) in combination with atezolizumab (anti-PD-L1) in patients with metastatic melanoma with the BRAF V600E mutation. Here, BRAF is linked to metastatic melanoma.